Venture capitalists in China are adopting different models to quickly create value from biopharma companies and are able to exit much faster than their U.S counterparts, new data suggest.
Interius Biotherapeutics Inc., which just closed on an oversubscribed $76 million series A financing, is fixed on simplifying CAR T-cell creation by making the process less cumbersome, less expensive and time consuming, and all done in vivo.
Less than a year after Novartis AG's acquisition of optogenetics specialist Vedere Bio Inc., its successor Vedere Bio II Inc. is launching with $77 million in series A financing, led by Octagon Capital. The company will develop earlier-stage assets than those Novartis purchased, including new, mutation-agnostic optogenetics technology to improve upon current gene therapies aimed at restoring functional vision to people with vision loss due to photoreceptor death.
LONDON – Technology commercialization specialist Eurekare SA has arrived on the scene after raising a $60 million series A, with which it plans to seed fund the formation of microbiome and synthetic biology startups and invest in later-stage rounds of companies specializing in those two fields.
PARIS – Readily3d SA has been awarded just under $600k by the European Union to develop a living model of the pancreas using its Tomolite 3D bioprinting technique. The European program, Enlight, boasts a total budget of $4.4 million provided by the European Innovation Fund 2020.
Soteria Biotherapeutics Inc., a company developing switchable bispecific T-cell engagers to treat patients with solid tumors, has raised $42 million in series A financing to fund early development of a pipeline of candidates with potential in validated cancer targets, it said. Roche Venture Fund and 5AM Ventures led the round, with further investments from M Ventures, Novartis Venture Fund and Alexandria Venture Investments.
RSS
